Drug Discovery

AstraZeneca recalls physician sample bottles of BRILINTA heart drug

AstraZeneca said that it is voluntarily recalling one lot of professional (physician) sample bottles containing eight tablets of BRILINTA (ticagrelor) 90mg tablets as a precautionary measure.

Harpoon Therapeutics raises $45m in new funding round

Harpoon Therapeutics has secured $45m in Series B financing, which included new investors Arix Bioscience, New Leaf Venture Partners and Taiho Ventures along with existing investor MPM Capital.

Nektar, Takeda to explore combination cancer therapy approaches

Nektar Therapeutics and Takeda Pharmaceutical have entered into a research collaboration to explore the combination of the former’s lead immuno-oncology candidate, the CD122-biased agonist NKTR-214, with five oncology compounds from the cancer portfolio of Takeda.

Iterum Therapeutics raises $65m in new financing round

Ireland-based Iterum Therapeutics, which is focused on the development and commercialization of anti-infectives for patients with infectious diseases and other acute illnesses, has raised $65m in a Series B investment round.

Biogen acquires Remedy Pharmaceuticals’ stroke drug

Biogen has acquired Remedy Pharmaceuticals' Cirara, a Phase 3 candidate in development for large hemispheric infarction (LHI).

IBM researchers find new method to simulate body’s immune response

IBM’s researchers have discovered how they can trigger the body’s immune response by using polymer-coated graphene sheets.

INC Research, inVentiv agree to merge in $4.6bn deal

INC Research has agreed to acquire US-based contract research organization (CRO) inVentiv Health in all stock deal worth nearly $4.6bn.

Vivet raises €37.5m to advance gene therapies for metabolic diseases

Vivet Therapeutics, which is focused on developing novel gene therapies for rare, inherited metabolic diseases, has raised €37.5m in a Series A financing round.

Poxel’s diabetes drug Imeglimin succeeds in phase 2b study in Japan

Poxel has announced positive top line results of a Phase 2b trial of Imeglimin for type 2 diabetes treatment in Japan.